PC
HALO icon

Paulson & Co’s Halozyme HALO Stock Holding History

Paulson & Co’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-111,100
Closed -$1.42M – 70
2017
Q2 		$1.42M Buy
+111,100
New +$1.48M 0.02% 97

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paulson & Co's HALO Position: Q3 2017 in Review

Paulson & Co sold out of Halozyme (HALO) in Q3 2017, closing a stake of 111,100 shares — an estimated $1.42M sold.

Paulson & Co first reported a position in HALO in Q2 2017 and held it in 1 quarter. The position peaked at $1.42M in Q2 2017. 166 funds tracked by Wall St. Rank hold HALO as of Q3 2017.

  • Paulson & Co reported no remaining Halozyme position as of Q3 2017 after selling out during the quarter.
  • Paulson & Co sold 111,100 Halozyme shares in Q3 2017, an estimated $1.42M.
  • Paulson & Co first reported a position in Halozyme in Q2 2017 and held it in 1 quarter.
  • Paulson & Co's Halozyme position peaked at $1.42M in Q2 2017.
  • 166 funds tracked by Wall St. Rank held Halozyme as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.